A personal account of a month on retatrutide, a drug still in trials and not approved for sale. It amounts to one person's anecdote, with no sourcing given.
Recap by typeshit. Full story at Iannique Renaud | Enforcer Reset.
One writer shares her own unexpected pregnancy while taking the tirzepatide shot, and says many others have been through the same thing.
Researchers looked at U.S. adults with type 2 diabetes starting a GLP-1 and estimate a small added risk of sudden vision loss that is often permanent.
Avi Roy says a Chinese supplier shipped retatrutide with a purity certificate, but a buyer's own germ test came back failed. A sharp look at gray-market risks.
An unsourced alert says compounded injectables, sermorelin included, face scrutiny over sterility. It names no regulator or official action.
Her view is that quicker loss on retatrutide doesn't automatically mean improved metabolic health. It's a short opinion post with no new data behind it.
17:56
DOWNSIZED looks at EASD 2026 data on an amylin-based drug reaching 23% weight loss and how it might stack up against retatrutide.
Loading…